Industry Trend

Site Sections

Menu








© 2023. All Rights reserved.

Overview for DAIICHI SANKYO

All Data per March 2, 2023

Industry:

Drug Manufacturers—General

Last Close:

4,468.00 JPY

Expected Dividend:

0.00 %

Payoffs per Year:

2.0
Business Summary
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Competitors View

Ordering

ABBVIE

USA		 1.03 4.28%
3.61%		 7.39% 5.46% 1.0 4.36
-9.47%		 43.02 13.08% 10.52 1.0

CHUGAI PHARMACEUTICAL

JPN		 0.96 2.56%
0.0%		 22.5% 6.68% 1.0 4.24
-32.13%		 32.9 15.38% 77.21 2.0

PFIZER

USA		 0.95 3.64%
3.96%		 2.76% 3.76% 1.0 3.02
-11.11%		 49.05 9.25% 42.54 3.0

ASTRAZENECA

GBR		 1.04 4.07%
2.74%		 1.15% 3.92% 1.0 11.56
-3.86%		 98.3 11.66% 37.27 4.0

DAIICHI SANKYO

JPN
 1.05 4.24%
0.0%		 0.0% 3.88% 1.0 8.15
-17.26%		 35.15 18.52% 61.0 5.0

SANOFI

FRA		 1.01 3.78%
4.03%		 0.74% 3.58% 1.0 0.57
-12.18%		 51.83 7.75% 57.12 6.0

BRISTOL-MYERS SQUIBB

USA		 0.98 2.8%
3.1%		 1.83% 2.78% 1.0 0.5
-24.44%		 34.92 17.8% 32.88 7.0

MERCK & CO.

USA		 1.12 3.12%
2.64%		 2.24% 3.15% 1.0 2.31
-11.68%		 55.47 10.37% 36.13 8.0

KYOWA HAKKO KOGYO

JPN		 0.96 1.88%
1.67%		 7.74% 2.44% 1.0 3.6
-15.61%		 35.6 3.07% 79.96 9.0

GILEAD SCIENCES

USA		 1.16 2.74%
3.6%		 5.91% 3.26% 1.0 0.15
-42.43%		 33.49 -1.11% 31.01 10.0

ELI LILLY AND COMPANY

USA		 1.04 2.43%
1.22%		 2.86% 2.52% 1.0 7.52
-12.71%		 42.91 5.87% 18.4 11.0

ROCHE

CHE		 0.92 3.28%
3.51%		 0.79% 3.11% 1.0 1.4
-15.85%		 37.23 2.14% 26.53 12.0

AMGEN

USA		 1.0 2.42%
3.28%		 8.46% 3.24% 1.0 3.5
-9.93%		 35.72 -5.0% 10.95 13.0

GLAXOSMITHKLINE

GBR		 0.96 5.37%
5.27%		 0.35% 5.0% -0.5 0.21
-24.56%		 49.96 2.63% 19.03 14.0

ASTELLAS PHARMA

JPN		 0.96 2.43%
0.0%		 1.74% 2.4% 1.0 1.09
-19.06%		 27.18 -1.76% 60.96 15.0

OTSUKA HOLDINGS CO., LTD.

JPN		 0.93 2.21%
2.54%		 0.0% 2.02% 1.0 -0.41
-14.62%		 28.52 12.2% 71.29 16.0

BAYER

GER		 1.02 2.51%
3.99%		 4.7% 2.83% 0.5 -0.36
-58.76%		 36.97 -17.89% 27.46 17.0

JOHNSON & JOHNSON

USA		 0.98 2.68%
0.0%		 0.0% 2.46% 1.0 -1.0
13.03%		 44.08 2.58% 40.67 18.0

GRIFOLS SA

ESP		 0.98 1.5%
nan%		 4.84% 1.7% -0.5 0.24
-46.29%		 31.86 -1.95% 31.7 nan

Information for DAIICHI SANKYO

Yield Triangle

Dividend & Close

Close Dividend Return (%)
Year
2012 440.67 60.00 13.62
2013 641.00 60.00 9.36
2014 562.67 60.00 10.66
2015 836.83 33.33 3.98
2016 797.17 21.67 2.72
2017 979.00 23.33 2.38
2018 1,170.33 23.33 1.99
2019 2,409.33 23.33 0.97
2020 3,535.00 52.17 1.48
2021 2,925.00 27.00 0.92
2023 4,468.00 0.00 0.00

Fundamentals

Chart